FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Exforge more effective than amlodipine alone

Exforge (valsartan/amlodipine) treatment results near twice as effective as amlodipine alone at reducing patients with high baseline blood pressure to a healthier blood pressure goal

Azor shows efficacy in difficult to treat patient groups

Data presented at ASH shows that Azor (amlodipine and olmesartan medoxomil) safely and effectively lowered blood pressure, especially in several key difficult to treat patient groups such as in those of African and Hispanic/Latino decent

Exforge treatment effective in black patients

Black patients treated with Exforge (Amlodipine/Valsartan) have been show to experience a significantly higher reduction in systolic blood pressure than those on amlodipine alone

Forest and Daiichi Sankyo end Azor co promotion agreement

Forest has terminated it’s co-promotion agreement for Azor (amlodipine and olmesartan medoxomil) with Daiichi Sankyo. Forest has determined that its resources will be better utilized in providing additional support for Forest’s currently marketed products.